SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Madam C. J. Walker

PatientSarah Walker
Date of birth1976-12-23
IdentifiersMRN HR-ET019-SYN; SSN (made up) 000-19-7062
Document date2026-08-17
AuthorHarriet Okonjo-Bell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review: blood pressure at goal, urine albumin, kidney function, hemoglobin, mood, and the travel season ahead. [S]

History of Present Illness

Madam Walker returns ten weeks after her preventive visit; the laboratory day was booked before her summer trips, as planned. Her home readings average 123/77 on losartan 100 mg, amlodipine 5 mg and empagliflozin 10 mg. She has had no ankle swelling, dizziness, genital itching or muscle aches. Her mammogram was normal and her HPV test and stool test were negative. Having read about APOL1 testing, she has decided not to have it for now, since it would not change her treatment; she knows it remains available. She plans an autumn of travel and asked what she should watch for on the road. [S]

ElementDetail
Home blood pressureAverage 123/77
ScreeningMammogram normal; HPV and stool tests negative
APOL1 testingDeclined for now, her choice
MoodPHQ-9 3

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo dizziness; weight down 3.2 kg since intake
CardiovascularNegativeNo ankle swelling or palpitations
GenitourinaryNegativeNo burning or genital itching
MusculoskeletalNegativeNo muscle aches
PsychiatricNegativeMood steady

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg oral tablet, one tablet each morningOne tablet each morning, at the same home time when travelingOral route2026-02-23 to 2026-03-09completedS
Losartan 100 mg oral tablet, one tablet each morningOne tablet each morningOral route2026-03-09activeS
Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet each morning, with sick-day rulesOral route2026-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-23activeS
Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two daysEvery 8 hours as needed for nausea, up to two daysOral route2026-04-13 to 2026-04-15completedS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-27activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-17Body height163cmS
2026-08-17Body weight75.8kgS
2026-08-17Body mass index (BMI) [Ratio]28.5kg/m2S
2026-08-17Systolic blood pressure122mm[Hg]S
2026-08-17Diastolic blood pressure76mm[Hg]S
2026-08-17Heart rate72/minS
2026-08-17Respiratory rate16/minS
2026-08-17Body temperature36.7CelS
2026-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-17Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-08-17Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-08-17Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-08-17Creatinine [Mass/volume] in Serum or Plasma1.3mg/dL0.59-1.04 mg/dLHighS
2026-08-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M50mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
2026-08-17Albumin/Creatinine [Mass Ratio] in Urine128mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
2026-08-17Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-08-17Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-08-17; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/76, pulse 72; weight 75.8 kg
CardiovascularRegular rhythm; no ankle swelling
RespiratoryClear

Problems

ProblemClinical statusVerificationCodeProvenance
Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressureactiveconfirmed I12.9S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis.
Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 2021 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6%activeconfirmed N18.31S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease.
Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate)activeconfirmed E78.5S — Synthetic laboratory finding.
Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolvedresolvedconfirmed A08.4S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings)Every visitCompleted today122/76
Self-managementHome blood pressure readingsTwo readings morning and evening for seven days to confirm and after each change; then twice a week, travel days includedCompleted todayAverage 123/77
ExaminationWeight and BMIEvery visitCompleted today75.8 kg, down 3.2 kg since intake
LaboratoryPotassium, bicarbonate, creatinine and eGFR (CKD-EPI 2021, race-free)Two to four weeks after starting or increasing losartan or empagliflozin; then every six monthsCompleted todayPotassium 4.8, bicarbonate 25 mmol/L; creatinine 1.30 mg/dL, eGFR 50
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; about three months after a treatment change; then every six months for G3a A2Completed today128 mg/g, 56% lower than baseline
LaboratoryHemoglobinYearly in CKD G3Completed today12.6 g/dL
LaboratoryCalcium, phosphate and parathyroid hormoneAt diagnosis of G3a, then every 6 to 12 monthsDueNormal at diagnosis; repeat at one year
SurveyKidney failure risk equation (4-variable), 2- and 5-yearYearly for G3 to G5Completed today5-year risk 1.7%
LaboratoryLipid panel and ALT4 to 12 weeks after starting a statin, then yearlyUp to dateLDL 98 mg/dL in April; yearly panel at one year
ExaminationFundus examinationYearlyDueDilated examination by an optometrist booked for the autumn
Medication safetyMedicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zonesEvery visitCompleted todayNo ankle swelling, dizziness, genital itching or muscle aches; sick-day card current
Medication safetyVaccination reviewYearly in CKDCompleted todayHepatitis B dose 2 given today; influenza and COVID-19 due in the autumn; zoster from 50
Self-managementSodium and diet counselingEvery visitCompleted todaySalt-free seasoning at home; restaurant choices on the road
SurveyDepression screen (PHQ-9)At intake, then yearlyCompleted todayPHQ-9 3
ReferralNephrology reviewAt diagnosis; then about six months, by video if she prefersDueVideo review with Dr. Achterberg booked for next month

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); Adult Immunization Schedule by Age (2026)

Follow-up: Video review with nephrology next month. Influenza and COVID-19 vaccines in the autumn; zoster after her birthday. Review in six months with urine albumin, kidney function, the yearly lipid panel and calcium, phosphate and parathyroid hormone, booked on a home day. Hold losartan and empagliflozin on days of vomiting, diarrhea or not eating. [S]